GlassScriptPhysician profile
Claudia Sofia Martinez-Serrano
NPI 1386425031
$4,696.95
in general payments reported to CMS, 2019-2025
47 companies · $1,235 in 2025
The $1,235 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $630 · 2024: $2,833 · 2025: $1,235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,497 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,497.01 |
| Education | $199.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $556.98 | 2023-2025 | |
| Celgene Corporation | $385.81 | 2024-2025 | Reblozyl, Pomalyst, Pomalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $331.01 | 2023-2025 | Ninlaro, Iclusig, Fruzaqla |
| Daiichi Sankyo INC. | $316.36 | 2024-2025 | Datroway, Enhertu, Injectafer |
| Abbvie INC. | $242.30 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $234.96 | 2023-2024 | Myrisk |
| Merck Sharp & Dohme LLC | $191.92 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Astrazeneca Pharmaceuticals LP | $184.80 | 2024-2025 | Imfinzi, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $162.62 | 2024-2025 | Opdivo, Krazati |
| Janssen Biotech, INC. | $155.95 | 2024-2025 | Rybrevant, Talvey, Darzalex |
| Lilly USA, LLC | $154.05 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $138.31 | 2023 | Padcev, Tukysa |
| Adaptive Biotechnologies Corporation | $136.88 | 2023-2024 | Clonoseq |
| Immunocore Limited | $126.52 | 2025 | Kimmtrak |
| Tersera Therapeutics LLC | $111.03 | 2023-2025 | Zoladex, Xermelo |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $109.75 | 2024-2025 | |
| Pharmaessentia USA Corporation | $92.08 | 2024 | Besremi |
| Incyte Corporation | $84.07 | 2023-2025 | Jakafi, Zynyz, Monjuvi |
| Genzyme Corporation | $80.22 | 2024-2025 | |
| Taiho Oncology, INC. | $74.11 | 2023-2024 | |
| Aveo Pharmaceuticals, INC. | $66.65 | 2024-2025 | |
| Array Biopharma INC | $65.37 | 2024-2025 | Mektovi, Xalkori, Lorbrena |
| Servier Pharmaceuticals LLC | $60.53 | 2025 | |
| Novartis Pharmaceuticals Corporation | $59.80 | 2025 | |
| Emmaus Medical, INC. | $46.86 | 2023-2024 | Endari |
| Kyowa Kirin, INC. | $46.85 | 2024 | Poteligeo |
| Stemline Therapeutics INC. | $43.00 | 2024 | Orserdu |
| Menarini Silicon Biosystems, INC. | $33.65 | 2024 | |
| Napo Pharmaceuticals INC | $30.51 | 2024 | Gelclair Concentrated Oral Gel |
| Astellas Pharma US INC | $29.98 | 2024 | Padcev |
| Alexion Pharmaceuticals, INC. | $26.67 | 2025 | Ultomiris |
| Glaxosmithkline, LLC. | $26.35 | 2025 | Jemperli, Zejula |
| Beone Medicines USA, INC. | $22.52 | 2025 | Tevimbra |
| Adc Therapeutics America, INC. | $22.00 | 2024 | |
| Exelixis INC. | $21.84 | 2024 | Cabometyx |
| Fennec Pharmaceuticals, INC. | $21.71 | 2025 | Fyarro |
| Beigene USA, INC. | $21.26 | 2024 | Brukinsa |
| Agios Pharmaceuticals, INC. | $21.08 | 2024 | |
| Genentech USA, INC. | $20.77 | 2024 | Venclexta |
| Novocure INC. | $20.20 | 2024 | Optune |
| Springworks Therapeutics, INC. | $19.53 | 2025 | Ogsiveo |
| Recordati_rare_diseases_inc. | $19.01 | 2024 | Sylvant |
| Sobi, INC | $18.84 | 2025 | |
| Amneal Pharmaceuticals LLC | $18.08 | 2023 | Avastin, Neupogen, Neulasta |
| Pharmacosmos Therapeutics INC. | $15.81 | 2024 | Cosela |
| Bayer Healthcare Pharmaceuticals INC. | $14.78 | 2025 | |
| Biogen, INC. | $13.57 | 2025 | Leqembi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudia Martinez-Serrano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.